New way to treat retinopathies suggested

Article

The discovery of factors affecting retinal angiogenesis have implications for the treatment of vascularization disorders, according to results of a study published in the October issue of Nature Medicine.

The discovery of factors affecting retinal angiogenesis have implications for the treatment of vascularization disorders, according to results of a study published in the October issue of Nature Medicine.

Sylvain Chemtob of the Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Quebec, Canada and colleagues investigated molecular causes of vision loss.

They found that a receptor found in neurons, G protein-coupled receptor-91 (GPR91), impacts the rate of vessel growth in hypoxic rodent retinas, regardless of whether they were examples of normal or ischaemic retinal development. The impact of GPR91 is tampered by retinal ganglion cells (RGCs), which, under certain conditions, regulate angiogenesis. Study subjects deficient in RGC were unable to moderate angiogenesis, implying a connection between GPR91 and proliferation of vascular networks.

The team therefore posited that there may be ways other than modulating vascular endothelial growth factor (VEGF) levels to treat abnormal vascularization. Specifically, modifying the activity of GPR91 might offer a more targeted and effective treatment for retinopathy. The team hopes to progress to human trials in three to four years.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.